688166 博瑞医药
已收盘 04-24 15:00:01
资讯
新帖
简况
每周股票复盘:博瑞医药(688166)博瑞转债或触发赎回条款
证券之星 · 04-26 02:46
每周股票复盘:博瑞医药(688166)博瑞转债或触发赎回条款
4月23日博瑞医药涨7.79%,科创创新药ETF国泰基金重仓该股
证券之星 · 04-23
4月23日博瑞医药涨7.79%,科创创新药ETF国泰基金重仓该股
博瑞医药(688166)披露“博瑞转债”预计满足赎回条件的提示性公告,4月20日股价下跌0.68%
证券之星 · 04-20
博瑞医药(688166)披露“博瑞转债”预计满足赎回条件的提示性公告,4月20日股价下跌0.68%
每周股票复盘:博瑞医药(688166)因股价涨幅达15%登龙虎榜
证券之星 · 04-19
每周股票复盘:博瑞医药(688166)因股价涨幅达15%登龙虎榜
龙虎榜 | 机构猛抛佛塑科技超2亿元,温州帮逾1.85亿出逃神剑股份
格隆汇 · 04-15
龙虎榜 | 机构猛抛佛塑科技超2亿元,温州帮逾1.85亿出逃神剑股份
4月15日博瑞医药(688166)龙虎榜数据:机构净买入6589.99万元,北向资金净买入5839.78万元
证券之星 · 04-15
4月15日博瑞医药(688166)龙虎榜数据:机构净买入6589.99万元,北向资金净买入5839.78万元
4月15日博瑞医药(688166)涨停分析:创新药进展、集采落地、政策加码驱动
证券之星 · 04-15
4月15日博瑞医药(688166)涨停分析:创新药进展、集采落地、政策加码驱动
A股收评 | 沪指微涨0.01% 伊朗局势突发!全球午后突变
智通财经网 · 04-15
A股收评 | 沪指微涨0.01% 伊朗局势突发!全球午后突变
每周股票复盘:博瑞医药(688166)补选非独立董事并披露转股进展
证券之星 · 04-05
每周股票复盘:博瑞医药(688166)补选非独立董事并披露转股进展
博瑞医药(688166)披露2025年年度股东会会议资料,4月2日股价上涨6.77%
证券之星 · 04-02
博瑞医药(688166)披露2025年年度股东会会议资料,4月2日股价上涨6.77%
百利天恒一持股5%以上股东完成减持计划;博瑞医药实控人提名女儿为董事|医药早参
每日经济新闻 · 04-02
百利天恒一持股5%以上股东完成减持计划;博瑞医药实控人提名女儿为董事|医药早参
每周股票复盘:博瑞医药(688166)BGM0504片减重幅度达8.2%
证券之星 · 03-29
每周股票复盘:博瑞医药(688166)BGM0504片减重幅度达8.2%
博瑞医药(688166)披露可转债保荐总结报告书,3月26日股价上涨1.88%
证券之星 · 03-26
博瑞医药(688166)披露可转债保荐总结报告书,3月26日股价上涨1.88%
博瑞医药美国一期研究显示:五至八周后平均体重下降2.7%-8.2%
美股速递 · 03-25
博瑞医药美国一期研究显示:五至八周后平均体重下降2.7%-8.2%
博瑞医药口服Bgm0504在中美两地肥胖症一期临床取得积极顶线结果
美股速递 · 03-25
博瑞医药口服Bgm0504在中美两地肥胖症一期临床取得积极顶线结果
博瑞医药Bgm0504一期临床试验总体耐受性良好 未出现严重不良事件
美股速递 · 03-25
博瑞医药Bgm0504一期临床试验总体耐受性良好 未出现严重不良事件
博瑞医药(688166)自愿披露关于BGM0504片减重适应症Ⅰ期临床试验数据的公告,3月24日股价下跌0.21%
证券之星 · 03-24
博瑞医药(688166)自愿披露关于BGM0504片减重适应症Ⅰ期临床试验数据的公告,3月24日股价下跌0.21%
博瑞医药(688166.SH):BGM0504片在中国和美国参与者上治疗成人超重/肥胖的I期临床试验取得积极结果
智通财经 · 03-24
博瑞医药(688166.SH):BGM0504片在中国和美国参与者上治疗成人超重/肥胖的I期临床试验取得积极结果
博瑞医药(688166)披露2025年持续督导跟踪报告,3月23日股价下跌0.69%
证券之星 · 03-23
博瑞医药(688166)披露2025年持续督导跟踪报告,3月23日股价下跌0.69%
博瑞医药(688166)2025年年报简析:净利润同比下降71.18%
证券之星 · 03-21
博瑞医药(688166)2025年年报简析:净利润同比下降71.18%
加载更多
公司概况
公司名称:
博瑞生物医药(苏州)股份有限公司
所属行业:
医药制造业
上市日期:
2019-11-08
主营业务:
博瑞生物医药(苏州)股份有限公司的主营业务是医药中间体、原料药和制剂产品的研发、生产。公司的主要产品是原料药-抗病毒类、原料药-抗真菌类、原料药-免疫抑制类、原料药-其他类、制剂类。在知识产权方面,公司高度重视知识产权工作,公司先后获得“国家知识产权示范企业”(国家知识产权局授予),“国家知识产权优势企业”(国家知识产权局授予),“2017年度中国专利优秀奖”(国家知识产权局授予),“第十一届中国药学会科学技术奖一等奖”等多项荣誉。报告期内,公司新提交国内专利申请67件,新获得国内专利授权25件;新提交国外专利申请25件,新获得国外专利授权3件;截至2025年12月末,公司累计申请专利598件,其中发明专利523件;拥有有效专利共297件,其中发明专利240件,布局了美国,日本,加拿大,欧洲,韩国等多个国家和地区。
发行价格:
12.71
{"stockData":{"symbol":"688166","market":"SH","secType":"STK","nameCN":"博瑞医药","latestPrice":59.99,"timestamp":1777014001000,"preClose":61.18,"halted":0,"volume":13922281,"delay":0,"changeRate":-0.0195,"floatShares":423000000,"shares":423000000,"eps":-0.1895,"marketStatus":"已收盘","change":-1.19,"latestTime":"04-24 15:00:01","open":60,"high":61.4,"low":58.6,"amount":831000000,"amplitude":0.0458,"askPrice":59.99,"askSize":85,"bidPrice":59.98,"bidSize":48,"shortable":0,"etf":0,"ttmEps":-0.1895,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":5,"adr":0,"adjPreClose":61.18,"symbolType":"stock_kcb","openAndCloseTimeList":[[1776994200000,1777001400000],[1777006800000,1777014000000]],"highLimit":67.3,"lowLimit":55.06,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":423104454,"isCdr":false,"pbRate":10.32,"roa":"--","roe":"2.17%","epsLYR":0.13,"committee":-0.155425,"marketValue":25382000000,"turnoverRate":0.0329,"status":1,"afterMarket":{"amount":11998,"volume":200,"close":59.99,"buyVolume":200,"sellVolume":0,"time":1777016037559,"indexStatus":"已收盘 04-24 15:30:00","preClose":61.18},"floatMarketCap":25382000000},"requestUrl":"/m/hq/s/688166","defaultTab":"news","newsList":[{"id":"2630801420","title":"每周股票复盘:博瑞医药(688166)博瑞转债或触发赎回条款","url":"https://stock-news.laohu8.com/highlight/detail?id=2630801420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630801420?lang=zh_cn&edition=full","pubTime":"2026-04-26 02:46","pubTimestamp":1777142773,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘,博瑞医药报收于59.99元,较上周的57.35元上涨4.6%。本周,博瑞医药4月23日盘中最高价报61.6元。本周关注点公司公告汇总:博瑞转债已有十个交易日股价不低于转股价130%,或触发赎回条款公司公告汇总关于“博瑞转债”预计满足赎回条件的提示性公告博瑞生物医药(苏州)股份有限公司于2022年1月4日发行465万张可转换公司债券,发行总额46,500万元,债券简称“博瑞转债”,代码118004,转股期为2022年7月11日至2028年1月3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629886571","title":"4月23日博瑞医药涨7.79%,科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629886571","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629886571?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:27","pubTimestamp":1776932831,"startTime":"0","endTime":"0","summary":"证券之星消息,4月23日博瑞医药涨7.79%创60日新高,收盘报61.18元,换手率5.21%,成交量22.06万手,成交额12.99亿元。重仓博瑞医药的前十大公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共10家,其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为12.41亿元,最新净值0.9451,较上一交易日上涨1.47%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300044789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166","589720"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628172916","title":"博瑞医药(688166)披露“博瑞转债”预计满足赎回条件的提示性公告,4月20日股价下跌0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628172916","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628172916?lang=zh_cn&edition=full","pubTime":"2026-04-20 22:05","pubTimestamp":1776693921,"startTime":"0","endTime":"0","summary":"截至2026年4月20日收盘,博瑞医药报收于56.96元,较前一交易日下跌0.68%,最新总市值为241亿元。近日,博瑞生物医药(苏州)股份有限公司发布《关于“博瑞转债”预计满足赎回条件的提示性公告》。公告显示,公司于2022年1月4日发行465万张可转换公司债券,发行总额46,500万元,债券简称“博瑞转债”,代码118004,转股期为2022年7月11日至2028年1月3日。截至2026年4月20日,公司股票已有十个交易日收盘价不低于当期转股价格的130%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000036450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628756111","title":"每周股票复盘:博瑞医药(688166)因股价涨幅达15%登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2628756111","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628756111?lang=zh_cn&edition=full","pubTime":"2026-04-19 01:46","pubTimestamp":1776534370,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘,博瑞医药报收于57.35元,较上周的53.06元上涨8.09%。本周,博瑞医药4月16日盘中最高价报59.5元。4月13日盘中最低价报46.0元。本周共计1次涨停收盘,无跌停收盘情况。博瑞医药当前最新总市值242.65亿元,在化学制药板块市值排名18/150,在两市A股市值排名888/5198。本周关注点来自交易信息汇总:博瑞医药因日收盘价格涨幅达到15%登上龙虎榜。此次是近5个交易日内第1次上榜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627288215","title":"龙虎榜 | 机构猛抛佛塑科技超2亿元,温州帮逾1.85亿出逃神剑股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2627288215","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627288215?lang=zh_cn&edition=full","pubTime":"2026-04-15 18:01","pubTimestamp":1776247302,"startTime":"0","endTime":"0","summary":"单日净买入额前三为汉缆股份、红板科技、博瑞医药","market":"fut","thumbnail":"https://img3.gelonghui.com/7fdae-009748c0-967f-4938-906f-d9a958b1bb6e.jpg?guru_height=852&guru_width=1280&guru_size=159383","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/7fdae-009748c0-967f-4938-906f-d9a958b1bb6e.jpg?guru_height=852&guru_width=1280&guru_size=159383"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4426773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["603459","BK0224","BK0028","BK0188","002083","688166","BK0037","BK0110","BK0131","BK0005","002498","BK0155","BK0220","BK0247","002560","002361","000973","BK0078","BK0229","BK0077","BK0107","BK0201","BK0239","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627384400","title":"4月15日博瑞医药(688166)龙虎榜数据:机构净买入6589.99万元,北向资金净买入5839.78万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627384400","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627384400?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:22","pubTimestamp":1776244926,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年4月15日公布的交易公开信息显示,博瑞医药因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年4月15日收盘,博瑞医药报收于57.66元,上涨20.0%,涨停,换手率6.73%,成交量28.49万手,成交额15.26亿元。从龙虎榜公布的当日买卖数据来看,机构合计净买入6589.99万元,北向资金合计净买入5839.78万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500031314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627409734","title":"4月15日博瑞医药(688166)涨停分析:创新药进展、集采落地、政策加码驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2627409734","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627409734?lang=zh_cn&edition=full","pubTime":"2026-04-15 15:33","pubTimestamp":1776238408,"startTime":"0","endTime":"0","summary":"证券之星消息,博瑞医药4月15日涨停收盘,收盘价57.66元。该股于11点22分涨停,1次打开涨停,截止收盘封单资金为1.21亿元,占其流通市值0.49%。今日博瑞医药涨停的可能因素有:BGM0504注射液国内III期临床完成入组、美国II期会议顺利结束,与华润三九达成商业化合作;地诺孕素片及布地奈德混悬液获批,4个产品拟中标国家集采接续采购;工信部吹风加快打造“创新医药”,明确支持创新药加速上市与合理定价,政策催化显著。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500022614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","159992","06978","BK1161","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627062554","title":"A股收评 | 沪指微涨0.01% 伊朗局势突发!全球午后突变","url":"https://stock-news.laohu8.com/highlight/detail?id=2627062554","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627062554?lang=zh_cn&edition=full","pubTime":"2026-04-15 15:08","pubTimestamp":1776236903,"startTime":"0","endTime":"0","summary":"截至收盘,沪指涨0.01%报4027.21点,成交10289亿元;深成指跌0.97%报14498.45点,成交13726亿元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260415/20260415150338_75294.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260415/20260415150338_75294.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["510300","159967","515890","000300.SH","002788","688166","600664","510880","399001","512510","000905.SH","002361","000688.SH","002808","000070","002926","002083","001208","301292","300502","512880","399006","688313","000001","600918","688353","600488","000919"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625619046","title":"每周股票复盘:博瑞医药(688166)补选非独立董事并披露转股进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2625619046","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625619046?lang=zh_cn&edition=full","pubTime":"2026-04-05 03:40","pubTimestamp":1775331623,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,博瑞医药报收于53.36元,较上周的49.52元上涨7.75%。公司公告汇总关于2025年年度股东会增加临时提案的公告:博瑞生物医药(苏州)股份有限公司董事会公告,股东袁建栋于2026年3月31日提交临时提案,提名Stephanie Yuan(袁芬妮)女士为公司第四届董事会非独立董事候选人。董事会提名委员会已审核其资格并认可其符合非独立董事任职条件。股本结构方面,无限售条件流通股和总股本相应增加603股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500001087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624574207","title":"博瑞医药(688166)披露2025年年度股东会会议资料,4月2日股价上涨6.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624574207","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624574207?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:02","pubTimestamp":1775120525,"startTime":"0","endTime":"0","summary":"截至2026年4月2日收盘,博瑞医药报收于54.39元,较前一交易日上涨6.77%,最新总市值为230.13亿元。该股当日开盘50.7元,最高55.5元,最低50.1元,成交额达11.75亿元,换手率为5.23%。博瑞医药于2026年4月2日披露《2025年年度股东会会议资料》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200028278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624408215","title":"百利天恒一持股5%以上股东完成减持计划;博瑞医药实控人提名女儿为董事|医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2624408215","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624408215?lang=zh_cn&edition=full","pubTime":"2026-04-02 07:00","pubTimestamp":1775084407,"startTime":"0","endTime":"0","summary":"|2026年4月2日星期四|NO.1百利天恒持股5%以上股东OAPIII(HK)Limited减持股份计划完成4月1日,百利天恒公告,因自身资金需求,OAPIII(HK)Limited拟通过集中竞价方式减持公司股份不超过4128738股,减持比例不超过公司总股本的1.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604023692459372.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023692459372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","BK1161","91194","09939","688166","688506","BK1515","BK0239","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623872243","title":"每周股票复盘:博瑞医药(688166)BGM0504片减重幅度达8.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623872243","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623872243?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:32","pubTimestamp":1774719131,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘,博瑞医药报收于49.52元,较上周的47.78元上涨3.64%。本周,博瑞医药3月27日盘中最高价报50.58元。博瑞医药自主研发的BGM0504片在中国和美国开展的I期临床试验取得积极结果。美国I期试验中,20~80mg剂量组给药5~8周后,减重幅度为2.7%~8.2%,主要为轻中度一过性胃肠道反应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622866028","title":"博瑞医药(688166)披露可转债保荐总结报告书,3月26日股价上涨1.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622866028","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622866028?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:16","pubTimestamp":1774534578,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘,博瑞医药报收于46.49元,较前一交易日上涨1.88%,最新总市值为196.7亿元。该股当日开盘46.1元,最高48.8元,最低45.4元,成交额达6.21亿元,换手率为3.12%。近日,国联民生证券承销保荐有限公司发布《关于博瑞生物医药(苏州)股份有限公司发行可转换公司债券并在科创板上市之保荐总结报告书》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600044239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149606458","title":"博瑞医药美国一期研究显示:五至八周后平均体重下降2.7%-8.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149606458","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149606458?lang=zh_cn&edition=full","pubTime":"2026-03-25 14:35","pubTimestamp":1774420513,"startTime":"0","endTime":"0","summary":"博瑞医药近日公布的一项美国一期临床试验数据表明,受试者在接受其研究性药物治疗五至八周后,平均体重降幅达到2.7%至8.2%。该结果凸显了药物在体重管理领域的潜在疗效,为后续临床开发提供了重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110229022","title":"博瑞医药口服Bgm0504在中美两地肥胖症一期临床取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1110229022","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110229022?lang=zh_cn&edition=full","pubTime":"2026-03-25 14:35","pubTimestamp":1774420512,"startTime":"0","endTime":"0","summary":"博瑞医药宣布,其口服药物Bgm0504针对肥胖症的一期临床试验在中美两地同步取得积极顶线结果。该数据标志着公司在代谢疾病创新药研发领域实现重要突破。\n研究显示,Bgm0504在安全性、耐受性及药代动力学特征方面均达到预期指标。这一进展为后续二期临床研究奠定了坚实基础,有望为全球肥胖症患者提供新的治疗选择。\n公司表示将加速推进该药物的国际化开发进程,并持续拓展其在代谢适应症领域的应用潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146306494","title":"博瑞医药Bgm0504一期临床试验总体耐受性良好 未出现严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1146306494","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146306494?lang=zh_cn&edition=full","pubTime":"2026-03-25 14:34","pubTimestamp":1774420460,"startTime":"0","endTime":"0","summary":"在近期完成的一期临床试验中,博瑞医药(股票代码:688166)旗下创新药Bgm0504展现出优异的安全性表现。研究数据显示,该药物总体耐受性良好,试验期间未报告任何严重不良事件。\n这一积极结果为后续临床研究奠定了重要基础。Bgm0504作为公司重点研发项目,其安全性的初步验证标志着药物开发取得关键进展。研究人员将继续推进后续临床试验,进一步评估该药物的有效性和安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621093390","title":"博瑞医药(688166)自愿披露关于BGM0504片减重适应症Ⅰ期临床试验数据的公告,3月24日股价下跌0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621093390","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621093390?lang=zh_cn&edition=full","pubTime":"2026-03-24 22:10","pubTimestamp":1774361448,"startTime":"0","endTime":"0","summary":"截至2026年3月24日收盘,博瑞医药报收于47.35元,较前一交易日下跌0.21%,最新总市值为200.34亿元。近日,博瑞医药发布《自愿披露关于BGM0504片减重适应症Ⅰ期临床试验数据的公告》。公告显示,公司自主研发的BGM0504片在中国和美国开展的I期临床试验取得积极结果。美国I期试验中,20~80mg剂量组给药5~8周后,减重幅度为2.7%~8.2%,主要为轻中度一过性胃肠道反应。数据支持BGM0504进入II期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400039766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621174052","title":"博瑞医药(688166.SH):BGM0504片在中国和美国参与者上治疗成人超重/肥胖的I期临床试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2621174052","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621174052?lang=zh_cn&edition=full","pubTime":"2026-03-24 16:23","pubTimestamp":1774340604,"startTime":"0","endTime":"0","summary":"智通财经APP讯,博瑞医药(688166.SH)发布公告,近日,博瑞生物医药(苏州)股份有限公司及全资子公司博瑞制药(苏州)有限公司(以下合称“公司”)自主研发的BGM0504片在中国和美国参与者上治疗成人超重/肥胖的I期临床试验取得了积极结果。BGM0504片是公司自主研发的GLP-1(胰高血糖素样肽1)和GIP(葡萄糖依赖性促胰岛素多肽)受体双重激动剂,属于境内外均未上市化学药品1类创新药。2025年8月和9月,公司分别收到美国食品药品监督管理局和中国国家药品监督管理局签发的《药物临床试验批准通知书》,同意BGM0504片在中国和美国参与者上开展关于成人超重/肥胖适应症的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博瑞医药(688166.SH):BGM0504片在中国和美国参与者上治疗成人超重/肥胖的I期临床试验取得积极结果","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621189774","title":"博瑞医药(688166)披露2025年持续督导跟踪报告,3月23日股价下跌0.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621189774","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621189774?lang=zh_cn&edition=full","pubTime":"2026-03-23 17:56","pubTimestamp":1774259772,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘,博瑞医药报收于47.45元,较前一交易日下跌0.69%,最新总市值为200.76亿元。该股当日开盘46.7元,最高49.15元,最低46.52元,成交额达7.01亿元,换手率为3.45%。近日,国联民生证券承销保荐有限公司发布《关于博瑞生物医药(苏州)股份有限公司2025年持续督导跟踪报告》。公司2025年净利润同比下降71.18%,主要受产品需求下滑、研发投入增加等因素影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300028325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621843757","title":"博瑞医药(688166)2025年年报简析:净利润同比下降71.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621843757","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621843757?lang=zh_cn&edition=full","pubTime":"2026-03-21 06:05","pubTimestamp":1774044329,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期博瑞医药发布2025年年报。根据财报显示,博瑞医药净利润同比下降71.18%。截至本报告期末,公司营业总收入12.24亿元,同比下降4.59%,归母净利润5451.47万元,同比下降71.18%。按单季度数据看,第四季度营业总收入3.49亿元,同比上升14.28%,第四季度归母净利润419.47万元,同比下降64.33%。从历史年报数据统计来看,公司上市以来中位数ROIC为10.68%,投资回报也较好,其中最惨年份2025年的ROIC为1.91%,投资回报一般。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032100004504.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777250145037,"stockEarnings":[{"period":"1week","weight":0.046},{"period":"1month","weight":0.3147},{"period":"3month","weight":0.1807},{"period":"6month","weight":0.1236},{"period":"1year","weight":0.4265},{"period":"ytd","weight":0.2228}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.0377},{"period":"3month","weight":-0.0136},{"period":"6month","weight":0.0328},{"period":"1year","weight":0.2374},{"period":"ytd","weight":0.028}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"博瑞生物医药(苏州)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20114人(较上一季度减少2.56%)","perCapita":"21035股","listingDate":"2019-11-08","address":"江苏省苏州市吴中区工业园区星湖街218号纳米科技园C25栋","registeredCapital":"42310万元","survey":" 博瑞生物医药(苏州)股份有限公司的主营业务是医药中间体、原料药和制剂产品的研发、生产。公司的主要产品是原料药-抗病毒类、原料药-抗真菌类、原料药-免疫抑制类、原料药-其他类、制剂类。在知识产权方面,公司高度重视知识产权工作,公司先后获得“国家知识产权示范企业”(国家知识产权局授予),“国家知识产权优势企业”(国家知识产权局授予),“2017年度中国专利优秀奖”(国家知识产权局授予),“第十一届中国药学会科学技术奖一等奖”等多项荣誉。报告期内,公司新提交国内专利申请67件,新获得国内专利授权25件;新提交国外专利申请25件,新获得国外专利授权3件;截至2025年12月末,公司累计申请专利598件,其中发明专利523件;拥有有效专利共297件,其中发明专利240件,布局了美国,日本,加拿大,欧洲,韩国等多个国家和地区。","listedPrice":12.71},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博瑞医药(688166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博瑞医药(688166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博瑞医药,688166,博瑞医药股票,博瑞医药股票老虎,博瑞医药股票老虎国际,博瑞医药行情,博瑞医药股票行情,博瑞医药股价,博瑞医药股市,博瑞医药股票价格,博瑞医药股票交易,博瑞医药股票购买,博瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博瑞医药(688166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博瑞医药(688166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}